Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Energy stocks elicit interest
Tue, 19 Nov 11:30 am

After opening positively, the Indian Indices are trading flat in the morning session. All sectoral indices except FMCG are trading in the green. The buying interest is the highest in capital goods and Energy stocks.

The BSE-Sensex is up 55 points and the NSE-Nifty is trading up 15 points. The BSE Mid Cap index is trading up 0.4% and the BSE Small Cap is trading up 0.2%. The Rupee is trading at 62.21 to the US Dollar.

Most Telecom stocks are trading positive today. Tata Communications and Bharti Airtel are among the stocks leading the gainers. According to a leading financial daily, India's Telecom regulator, TRAI has rejected the recommendations of the Telecom Commission regarding the auction of the 800 MHz spectrum. The telecom commission, which is the country's primary policy making authority in the Telecom sector, had recommended that TRAI take back its decision to not auction the 800 MHz spectrum. Spectrum in this bandwidth is currently used by CDMA players, Tata Teleservices, Reliance Communication and Sistema Shyam Teleservices. TRAI had recommended that this spectrum, instead of being auctioned, should be reserved for GSM companies, so that they would be able to roll out their extended GSM (eGSM) services. This decision was heavily criticized by the CDMA firms. The final call on this contentious issue will now be taken by the Department of Telecom (DoT).

Indian Pharma stocks are trading mixed today. Indoco Remedies and Panacea Biotech are leading the gainers, while Dishman Pharma and Natco Pharma are leading the losers. According to a filing on the BSE; Ipca Laboratories has entered into an agreement with Avik Pharmaceutical Ltd to acquire 50% stake in the company. IPCA will acquire 50% of its paid-up equity share capital. This will be carried out partly through purchase of equity shares from existing shareholders and the rest through subscription to its fresh equity share capital on a preferential allotment basis. The total acquired capital would be about Rs 65 m. Avik Pharmaceutical is a private company and engaged in the development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs). IPCA is trading flat today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Energy stocks elicit interest". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.